Trial Profile
A retrospective study assessing patterns of use and effectiveness of neoadjuvant pertuzumab-containing regimens in stage II-III HER2-neu positive breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2018
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Anthracyclines; Carboplatin; Cyclophosphamide; Taxanes; Trastuzumab
- Indications Breast cancer
- Focus Therapeutic Use
- 16 Jan 2018 New trial record
- 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium